Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial

Lancet Oncology

Volumn 6, Issue 10, 2005, Pages 757-764

  Overgaard, Jens ^a   Eriksen, Jesper Grau ^a   Nordsmark, Marianne ^a   Alsner, Jan ^a   Horsman, Michael R ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

NIMORAZOLE; OSTEOPONTIN; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOXIA; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; PHARYNX CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CHILD; DOUBLE-BLIND METHOD; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NIMORAZOLE; OSTEOPONTIN; PLACEBOS; RADIATION-SENSITIZING AGENTS; SIALOGLYCOPROTEINS; SURVIVAL ANALYSIS;

EID: 26444467146     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70292-8     Document Type: Article

References (31)

1. J Overgaard MR Horsman Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers Semin Radiat Oncol 6 1996 10-21
2. P Vaupel M Höckel Oxygenation of human tumors in: M Molls P Vaupel (Eds) Medical radiology: Blood perfusion and microenvironment of human tumors 1998 Springer-Verlag Berlin Heidelberg New York 63-72
3. J Overgaard Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors Oncol Res 6 1994 509-518
4. JM Brown WR Wilson Exploiting tumour hypoxia in cancer treatment Nat Rev Cancer 4 2004 437-447
5. M Höckel P Vaupel Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects J Natl Cancer Inst 93 2001 266-276
6. M Nordsmark J Overgaard Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer Acta Oncol 43 2004 396-403
7. M Nordsmark SM Bentzen V Rudat et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multicenter study Radiother Oncol 2005 published online Aug 10 (DOI:10.1016/j.radonc.2005.06.038)
8. NJ Beasley R Leek M Alam et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: Relationship to tumor biology and treatment outcome in surgically resected patients Cancer Res 62 2002 2493-2497
9. M Nordsmark J Alsner J Keller et al. Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations Br J Cancer 84 2001 1070-1075
10. C Leo AJ Giaccia NC Denko The hypoxic tumour microenvironment and gene expression Semin Radiat Oncol 14 2004 207-214
11. QT Le NC Denko AJ Giaccia Hypoxic gene expression and metastasis Cancer Metastasis Rev 23 2004 293-310
12. J Overgaard HS Hansen M Overgaard et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85 Radiother Oncol 46 1998 135-146
13. M Nordsmark SM Bentzen J Overgaard Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity Acta Oncol 33 1994 383-389
14. M Nordsmark J Loncaster C Aquino-Parsons et al. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas Radiother Oncol 67 2003 35-44
15. L Bentzen S Keiding M Nordsmark et al. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours Radiother Oncol 67 2003 339-344
16. 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors Radiother Oncol 73 2004 359-366
17. J Bussink JH Kaanders AJ van der Kogel Tumor hypoxia at the micro-regional level: Clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers Radiother Oncol 67 2003 3-15
18. BS Sørensen J Hao J Overgaard et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes Radiother Oncol 2005 published online Aug 10 (DOI:10.1016/j.radonc.2005.06.037)
19. GJ Hutchison HR Valentine JA Loncaster et al. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: Correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix Clin Cancer Res 10 2004 8405-8412
20. DM Aebersold P Burri KT Beer et al. Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer Cancer Res 61 2001 2911-2916
21. JH Kaanders KI Wijffels HA Marres et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer Cancer Res 62 2002 7066-7074
22. QT Le PD Sutphin S Raychaudhuri et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas Clin Cancer Res 9 2003 59-67
23. 2 measurements in advanced head and neck tumors treated by radiotherapy European Journal of Cancer Supplements 1 2003 S145
24. J Sodek B Ganss MD McKee Osteopontin Crit Rev Oral Biol Med 11 2000 279-303
25. PY Wai PC Kuo The role of osteopontin in tumor metastasis J Surg Res 121 2004 228-241
26. SR Rittling AF Chambers Role of osteopontin in tumour progression Br J Cancer 90 2004 1877-1881
27. 2 and prognosis in head and neck squamous cell carcinomas J Clin Oncol 23 suppl 16 2005 5521
28. DG Altman B Lausen W Sauerbrei M Schumacher Dangers of using "optimal" cutpoints in the evaluation of prognostic factors J Natl Cancer Inst 86 1994 829-835
29. JH Kaanders J Bussink AJ van der Kogel ARCON: A novel biology-based approach in radiotherapy Lancet Oncol 3 2002 728-737
30. D Rischin L Peters R Fisher et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02) J Clin Oncol 23 2005 79-87
31. 18F-misonidazole (FMISO) pet scanning J Clin Oncol 22 suppl 14 2004 5520